and the European Board for Accreditation in Cardiology (EBAC) to provide continuing medical education for physicians.
This suggests that the improvement in myocardial infarct size by SGLT2
inhibition may occur independent of the glycemic status.
Canagliflozin improved hyperglycemia in diabetic rats but importantly did not cause hypoglycemia in nondiabetic rats.
Short-term perfusion of the nondiabetic heart with canagliflozin, solubilized in the Langendorff perfusion buffer, had no impact on the myocardial infarct size. 
SUMMARY
The authors hypothesized that despite similar cardiovascular event rates, the improved cardiovascular survival from sodium glucose transporter 2 (SGLT2) inhibition, seen clinically, could be via a direct cytoprotective effect, including protection against myocardial ischemia/reperfusion injury. Langendorff-perfused hearts, from diabetic and nondiabetic rats, fed long-term for 4 weeks with canagliflozin, had lower infarct sizes; this being the first demonstration of canagliflozin's cardioprotective effect against ischemia/reperfusion injury in both diabetic and nondiabetic animals. By contrast, direct treatment of isolated nondiabetic rat hearts with canagliflozin, solubilized in the isolated Langendorff perfusion buffer, had no impact on infarct size. This latter study demonstrates that the infarct-sparing effect of long-term treatment with canagliflozin results from either a glucose-independent effect or up-regulation of cardiac prosurvival pathways. These results further suggest that SGLT2 inhibitors could be repurposed as novel cardioprotective interventions in high-risk In designing our experiments, we observed that whereas the survival curves in the EMPA-REG and CANVAS trials separate quickly, it still takes weeks to see the survival curves diverge. As such, we undertook to treat both diabetic and nondiabetic rats for a period of 4 weeks. Moreover, because treatment with an SGLT2 inhibitor will invariably affect circulating blood glucose at the time of myocardial infarction in vivo, we harvested the hearts and undertook the Lim et al. Finally, we wished to ascertain whether the SGLT2 inhibitor would have a direct, cardioprotective effect in the isolated heart, and to this end, we undertook a further group of experiments with "acute" exposure to the SGLT2 inhibitor, with the drug added to the Langendorff perfusate throughout the perfusion protocol.
Using the SGLT2 inhibitor, canagliflozin, in a reverse-translational study, we found that long-term pre-administration over 4 weeks led to a significant 
METHODS
For a detailed description of all methods, see the Supplemental Appendix. In brief, ZL and ZDF rats were monitored weekly with random blood glucose (A) Body weight index. The diabetic ZDF rats were significantly larger than the nondiabetic ZL rats. Canagliflozin administration in the ZL led to a significant reduction in body mass index that was absent in the ZDF diabetic rats. n ¼ 8 to 10 per group. (B) Random glucose concentration on day of experiment. As expected, ZDF diabetic rats had significantly higher blood glucose concentrations compared to the nondiabetic ZL controls (p < 0.0001; n ¼ 6 to 9 per group). Canagliflozin had no impact upon blood glucose in the ZL group (p ¼ NS; n ¼ 9 to 10 per group), but significantly reduced glucose in the diabetic ZDF rats (p < 0.0001; n ¼ 6 to 9 per group). (C to E) Renal manifestations of diabetes in the ZDF rats. (C) Urine glucose, measured by urinalysis strip test. No glucosuria was detectable in the control ZL rats, but there was significant glucosuria in ZL rats on canagliflozin. As expected, significant glucosuria was found in both ZDF control and canagliflozin- Lim et al. Unexpectedly, we found that diabetic rats treated with canagliflozin were heavier than untreated Thirty-six animals were started into the study, of which 29 completed through to analysis. Reasons for and timings of animal exclusions shown in all groups. Pre priori exclusion criteria are shown in the Supplemental Appendix. Abbreviations as in Figure 1 . For this investigation, we used 36 animals. Of these, 9 had to be excluded for reasons summarized in Figure 3 . Twenty-seven animals completed the full experimental protocol.
We found a small, but significant, difference between myocardial infarct size in the control arms of the diabetic ZDF and the nondiabetic ZL rat heart groups (p ¼ 0.04) ( Figure 4A , Supplemental Figure 2 ).
This difference is expected in Langendorff-perfused hearts where glucose is the sole energy substrate (see review [8] ). We found that canagliflozin, mir- Table 1 ). No rats had to be excluded from this study, and all rat data were included in the final analysis.
Of note, short-term, ex-vivo canagliflozin failed to significantly alter infarct size, with treatment versus control of 38 AE 3% versus 45 AE 4%, respectively (p ¼ 0.15) ( Figure 5A ). There was no difference in the area at risk between any of the groups ( Figure 5B ).
DISCUSSION
Our study provides the first evidence to our knowledge that long-term oral administration of canagliflozin over a period of 4 weeks is cardioprotective, ameliorating myocardial infarct size in both diabetic and nondiabetic rats, independent of glucose concentration at the time of ischemia/reperfusion injury.
The latter observation, that canagliflozin-induced protection in the nondiabetic rat, is particularly noteworthy: a clinically available SGLT2 inhibitor, canagliflozin, appears to have a cardiovascular and cardioprotective role that extends beyond (and probably also independent of) its intended indication in the management of hyperglycemia in type 2 diabetes mellitus.
LONG-TERM ORAL CANAGLIFLOZIN ATTENUATES MYOCARDIAL INFARCTION IN THE DIABETIC RAT.
In the diabetic ZDF rats, attenuating the extent of Lim et al. washout before ischemia, suggests a mechanism that imbues a "memory," potentially through the recruitment of signaling pathways. And if a signaling pathway, it is a pathway whose efficacy, unlike that of ischemic conditioning (11), is seemingly not affected by the presence of significant diabetes (the severity of the diabetic phenotype confirmed by evidence of the development of nephropathy). One such mechanism may be through a Jak-STAT3 pathway, as suggested by Iliodromitis's group (9)-but there may be others.
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SGLT2 Inhibition Attenuates Myocardial Infarction
LONG-TERM ORAL CANAGLIFLOZIN ATTENUATES MYOCARDIAL INFARCTION IN THE NONDIABETIC
RAT. Although the observation that canagliflozin attenuates infarct size in the diabetic rat is important, the principal novelty in this study comes from our data in the nondiabetic group of animals. We observe that long-term oral canagliflozin administration significantly reduces myocardial infarct size in the nondiabetic ZL rat heart. These data have 3 provocative implications:
1. The potentially paradigm-shifting observation that SGLT2 inhibitors may be repurposed for the management of high-risk nondiabetic patients with significant pre-existing cardiovascular disease.
2. Canagliflozin is not a pure diabetic drug, and possesses pleiotropic effects that extend beyond purely lowering serum glucose.
3. The cardioprotective effect of canagliflozin is only manifest when administered orally over a period of weeks, which challenges current thinking in terms of mechanisms that appear to extend beyond a direct effect upon either the myocardium or kidney.
EX-VIVO CANAGLIFLOZIN FAILS TO PROTECT THE
NONDIABETIC RAT HEART. In contrast to the longterm oral administration, the short-term administration of canagliflozin, ex vivo, administered at a concentration of 10 mmol/l (equivalent to the circulating concentration in patients taking canagliflozin, 300 mg once daily [7] ) throughout the perfusion protocol, The sodium hydrogen exchange (NHE) hypothesis appeared to be a strong and attractive contender to explain the cardioprotection in our long-term canagliflozin administration studies (16, 17) . Previous investigations using cariporide and amiloride in animal models reveal highly efficacious anti-ischemic benefits of NHE inhibition against myocardial infarction, particularly when administered before the onset of myocardial ischemia (18) (19) (20) (21) . Thus, we had anticipated the short-term ex vivo study to provide further evidence of infarct size limitation. Indeed, in the excellent study from Zuurbier's group (17) , with 3 mmol/l canagliflozin, they demonstrated highly effective attenuation of NHE activity. Given the similarity in concentration of canagliflozin in our and in Zuurbier's cell-based model, we were surprised that we found no protection in our ex-vivo model.
Might the protective effects of long-term administration of canagliflozin be mediated through NHE inhibition? Encouragingly, protection was observed in both diabetic and nondiabetic animals as expected.
However, with 40 min of washout before induction of ischemia, it seems somewhat unlikely that significant quantities of canagliflozin would remain within the heart. Our data would therefore appear to suggest that the observed protection from long-term administration of canagliflozin is less likely to be mediated through NHE inhibition, but perhaps through another pleiotropic pathway capable of triggering a "memory" effect through activation of signaling cascades.
Already identified candidate pathways include the aforementioned Jak/STAT3 pathway (9) that may also help attenuate oxidative stress and fibrotic myocardial remodeling (22) or perhaps through AMPK (23) (also found in kidney to reduce ischemia/reperfusion injury [24] ), although these are not hypotheses that we have yet tested. The renoprotective effects of SGLT2 inhibition typically take many months to manifest (2, 26) , which contrasts with the comparatively rapid separation of the cardiovascular outcome curves. We designed our study primarily as an investigation into cardioprotection; a study with renoprotection as a primary endpoint would likely mandate a much longer duration of drug treatment.
DIABETIC COMPLICATIONS. It was initially surprising that the only serious, life-threatening complication found during our long-term study was infective.
As might have been anticipated, the source of infection was, in both cases, urinary tract. However, these 2 events were in the nontreated control diabetic ZDF rats and not in animals treated with canagliflozin. In total, 2 animals in the control ZDF group had to be euthanized for serious sepsis; neither of the canagliflozin-treated groups (diabetic or nondiabetic)
had evidence of septic complications. Both diabetic ZDF groups had significant glycosuria, whereas the untreated control ZDF also had significant hyperglycemia. The sepsis, therefore, is much more likely to be secondary to the uncontrolled diabetes in the control animals, whereas the infective risk associated with canagliflozin-induced glucosuria was easily managed by simple animal husbandry and hygiene methods. No animal deaths were found related to cardiovascular causes, but our study was not powered for this endpoint, nor was it run for a sufficient period for such complications to become manifest.
STUDY LIMITATIONS.
In designing our studies, we accepted a number of compromises. To avoid the confusion that may ensue with polypharmacy, we did not treat the control diabetic animals to manage their hyperglycemia. These animals displayed high levels of glycemia, and 2 animals had septic complications that were rapidly identified and managed. We therefore feel that prolonging the duration of study beyond 4 weeks as designed would not have been feasible.
However, the infarct size data are compelling:
administering canagliflozin, irrespective of diabetic status, resulted in a pronounced reduction of myocardial infarct size.
As all diabetic patients in the clinical outcome studies were undertaken in the presence of antihyperglycemic agents, a future study may be constructed at the outset to include diabetic animals managed with metformin, the backbone of contemporary type 2 diabetic management. Indeed, this may well be mandated in any future study designed to look at cardiovascular complications and renal outcomes where much longer treatment periods would need to be considered.
We do not believe that the severity of the diabetes had an adverse impact upon the outcome of our study; in fact, the infarct size of the diabetic animals was entirely in line with previous short-term studies in other diabetic models (such as streptozocin-treated or Goto-Kakizaki lean diabetic rats) and from our own group and others (27, 28 Lim et al.
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